Biocon Biologics Receives Japanese Approval for Pegfilgrastim Biosimilar
Biocon Biologics, a subsidiary of Biocon Ltd, has received marketing approval from Japan's Ministry of Health, Labour and Welfare for its pegfilgrastim biosimilar, a cancer supportive care drug used to reduce infection risk after chemotherapy. The product, a biosimilar to Neulasta, will be exclusively promoted and distributed in Japan by Sandoz K.K. This approval expands Biocon's biosimilar portfolio in Japan and supports its goal of increasing patient access to affordable medications globally.
First-hand measurement across 4 sources
We measured how 4 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (63/100). Lens Score 45/100.
Outlets measured: economictimes, news18, businessstandard, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 25 Aug, 03:39 am. Other outlets followed.